PREPARATION AND SAFE USE OF

PMMA BONE CEMENT

Grant Funds provided by

(A Continuing Education Self-Study Activity)

A Continuing Education Activity

Sponsored By

Certified for 1 AST, RN, or CBSPD credit

Grant Funds Provided By

GOING GREEN IN THE OR

Welcome to

PREPARATION AND SAFE USE OF PMMA BONE CEMENT

(A Continuing Education Self-Study Activity)

CONTINUING EDUCATION INSTRUCTIONS

This educational activity is intended for use as a stand alone self-study activity. We suggest you take the
following steps for successful completion:
1. Read the overview and objectives to ensure consistency with your own learning needs and objectives.
2. Review the content of the self-study activity, paying particular attention to those areas that reflect the
objectives.
3. Complete the Test Questions and compare your responses with the answers provided.
4. For additional information on an issue or topic, consult the references.
5. To receive credit for this activity complete the evaluation and registration form.
6. Print your certificate, and make note and save the transaction ID number to retrieve your certificate at a
later date.
If you have any questions, please call: 720-748-6144.

CONTACT INFORMATION:

2101 S. Blackhawk Street, Suite 220

Aurora, CO 80014-1475
Phone: 720-748-6144
Fax: 720-748-6196
Website: www.pfiedlerenterprises.com
Pfiedler Enterprises - all rights reserved 2011

Preparation and Safe Use of PMMA Bone Cement

OVERVIEW
Polymethylmethacrylate (PMMA), commonly referred to as bone cement, continues to play a vital role as one of the primary
synthetic biomaterials used in orthopedic surgery. The safe and effective use of bone cement is a critical factor in the
success of many total joint arthroplasty procedures today. Accurate cement mixing and precise application techniques both
increases the stability and the longevity of the prosthesis. Therefore, these techniques are the foundation of successful
outcomes for the patient undergoing cemented arthroplasty procedures. In addition, safe handling of PMMA in the operating
room is essential to ensure that the potential associated health risks both to patients and healthcare workers are minimized.
Therefore, it is critical that perioperative personnel involved in the preparation and use of PMMA bone cement are aware of
these potential risks and that they handle bone cement in a manner that minimizes them. This continuing education activity
will provide a review of the key clinical considerations related to the preparation and safe use of PMMA bone cement. The
historical evolution of the development of bone cement and the progressive advances briefly will be reviewed. The science
of bone cement, including its components and the various types of cement, such as antibiotic impregnated cement, will be
discussed. The indications and contraindications for the use of bone cement and the key criteria for patient selection, as
well as the appropriate type of bone cement, will be outlined. The evolution of mixing and application techniques also will be
presented. The potential hazards associated with the use of bone cement, including bone cement implantation syndrome,
will be discussed. This will be followed by a review of key measures for the safe use of bone cement which will reduce the
risk of exposure in both patients and members of the surgical team.

OBJECTIVES

Upon completion of this continuing education activity, the participants should be able to:

1. Discuss the historical evolution of the development and use of bone cement.
2. Describe the components of bone cement and the various types available today.
3. Outline the indications and contraindications for the use of bone cement.
4. Describe various cement mixing and application techniques.
5. Identify the hazards associated with the use of PMMA in the perioperative practice setting.
6. Discuss key safety precautions that are required to prevent excessive exposure to PMMA ingredients both in patients
and healthcare workers.

INTENDED AUDIENCE

This continuing education activity is intended for perioperative nurses, surgical technologists, and other health care professionals who
are involved in the care of patients undergoing cemented total joint arthroplasty. This study guide will assist those who are interested in
learning more about the key safety considerations in the preparation and use of PMMA bone cement.

CREDIT/CREDIT INFORMATION
State Board Approval for Nurses

Pfiedler Enterprises is a provider approved by the California Board of Registered Nursing, Provider Number CEP14944, for 2.0 contact
hour(s).
Obtaining full credit for this offering depends upon attendance, regardless of circumstances, from beginning to end. Licensees must
provide their license numbers for record keeping purposes.

The certificate of course completion issued at the conclusion of this course must be retained in the participants records for
at least four (4) years as proof of attendance.

AST Credit for Surgical Technologists

This continuing education activity is approved by the Association of Surgical Technologists, Inc. for (2.0) CE credits for continuing
education in surgical technology.

IACET Credit for Allied Health Professionals

Pfiedler Enterprises has been approved as an Authorized Provider by the International Association for Continuing Education and
Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102.

CEU STATEMENT

As an IACET Authorized Provider, Pfiedler Enterprises offers CEUs for its programs that qualify under IACET guidelines. Pfiedler
Enterprises is authorized by IACET to offer 0.2 CEU (2.0 contact hours) for this program.

RELEASE AND EXPIRATION DATE

This continuing education activity was planned and provided in accordance with accreditation criteria. This material was originally
produced in September 2011 and can no longer be used after September 2013 without being updated; therefore, this continuing
education activity expires in September 2013.

DISCLAIMER

Accredited status as a provider refers only to continuing nursing education activities and does not imply endorsement of any products.

SUPPORT

Grant funds for the development of this activity were provided by Stryker.

PLANNING COMMITTEE
Rose Moss, RN, MN, CNOR
Nurse Consultant
Moss Enterprises

Larkspur, CO

Judith Pfister, RN, BSN, MBA

Program Manager
Pfiedler Enterprises

Aurora, CO

EXPERT REVIEWERS
Chad Edmonson, CST
Certified Surgical Technologist
Sky Ridge Medical Center

Lone Tree, CO

Julia A. Kneedler, RN, MS, EdD

Director of Education
Pfiedler Enterprises

Aurora, CO

Donna Reeves, BA, MA, MEd, PhD

Consultant
Pfiedler Enterprises

Aurora, CO

DISCLOSURE INFORMATION

All planning committee members, expert reviewers, and authors participating in continuing education activities sponsored by Pfiedler
Enterprises are expected to disclose to the audience any real or apparent financial affiliations related to the content of their activities.
Detailed disclosure appears below. For live presentations disclosure will be made verbally.
Planning committee members, expert reviewers, authors and faculty information:

1. Have you (or your spouse/partner) had any personal financial relationship in the last 12 months with the manufacturer
of the products or services that will be presented in this continuing education activity (planner/reviewer) or in your
presentation (speaker/author)?
2. Type of affiliation/financial interest with name of corporate organization.
3. Will your presentation include discussion of any off-label or investigational drug or medical device?
Rose Moss, RN, MN, CNOR
1. No
2. None
3. No
Judith Pfister, RN, BSN, MBA
1. Yes
2. Co-owner of company that receives grant funds from commercial entities
3. No
Chad Edmonson, CST
1. No
2. None
3. No
Julia A. Kneedler, RN, MS, EdD
1. Yes
2. Co-owner of company that receives grant funds commercial entities
3. No
Donna Reeves, BA, MA, MEd, PhD
1. No
2. None
3. No

PRIVACY AND CONFIDENTIALITY POLICY

Pfiedler Enterprises is committed to protecting your privacy and following industry best practices and regulations regarding
continuing education. The information we collect is never shared with other organizations for commercial purposes. Our
privacy and confidentiality policy covers the site www.pfiedlerenterprises.com and is effective on March 27, 2008.
To directly access more information on our Privacy and Confidentiality Policy, type the following URL address into your
browser: http://www.pfiedlerenterprises.com/privacy-policy. In addition to this privacy statement, this website is compliant
with the guidelines for internet-based continuing education programs.
The privacy policy of this website is strictly enforced.

CONTACT INFORMATION
If site users have any questions or suggestions regarding our privacy policy, please contact us at:
Phone:

720-748-6144

Email:

tonia@pfiedlerenterprises.com

Postal Address:

2101 S. Blackhawk Street, Suite 220

Aurora, Colorado 80014

Website URL:

http://www.pfiedlerenterprises.com

INTRODUCTION
Polymethylmethacrylate (PMMA), commonly known as bone cement, is a widely used method of implant fixation; this
technique has largely contributed to the success of modern joint replacement.1 As will be discussed, cement is a
misnomer because, in general, the word cement is used to describe a substance that bonds two things together.2 Thus the
term cement implies that the material sticks the implant into the bone; in reality, however, PMMA should be called bone
grout, because it acts as a space-filler that creates a tight space which holds the implant against the bone.
Bone cement is the only implant that is manufactured in the operating room (OR). None the less, it must meet the same
high standards that are demanded of any other implant supplied by the industry.3 In addition, due to its composition, PMMA
has unique safety considerations that are related to its preparation and its use in the OR. Accurate bone cement mixing and
precise application techniques are the foundation of successful patient outcomes, as they both increase the stability and the
longevity of the prosthesis. Also, safe handling of PMMA bone cement is critical in ensuring that the potential health risks to
both patients and healthcare professionals are minimized.

HISTORICAL EVOLUTION OF BONE CEMENT

The development of bone cement has played a key role in refining and improving surgical techniques for cemented
total joint arthroplasty. Since its development, the widespread use of bone cement has contributed to successful joint
replacement and patient outcomes.
Cementing with self-curing substances was the first, and initially the only, technique to achieve a stable fixation of the
implants. Themistokles Gluck, a German surgeon, was the first surgeon to implant a total knee prosthesis made of ivory in
1870. He fixed the stems in both the tibia and the femur with a cement that he mixed of plaster and colophony, which cured
up to the hardness of glass.4
Dr. Otto Rohm first synthesized a group of thermoplastics, i.e., acrylic polymers, and introduced them into commercial use in
the 1930s. In their earliest applications, these acrylics replaced hard rubber as the base materials for dentures.5
Sir John Charnley, is considered the founder of modern artificial joint replacement. He developed the art and science
of modern cementing technique in the late 1950s, as he searched for ways to fix the femoral component as part of the
development of his low friction arthroplasty.6 Dr. Charnley wanted a material that was resistant to body fluids, viscous with a
low toxicity, could be easily manipulated, and would set within a reasonable time. After experimenting with various materials,
he eventually settled on polymethylmethacrylate - a viscous dough which he formed by mixing the powder with the liquid
monomer. Dr. Charnley used cold-cured PMMA to attach an acrylic cup to the femoral head and to seat a metallic femoral
prosthesis; this was a significant milestone in the advancement of orthopedic surgical procedures. Also, Dr. Charnley was
the first to realize that PMMA easily could be used to fill the medullary canal and to blend with the bone morphology. The
cement served to increase the biomechanical stability and to decrease the stress on the implant; he settled on the idea of
using cement as a grout for the hip implants.
In the 1960s, bone cement was not available widely in the United States because it was not approved for use in total
hip surgery. In the 1970s, the U.S. Food and Drug Administration (FDA) approved bone cement for use in hip and knee
prosthetic fixation.7 Since then, while bone cement has become widely used for fixation of prostheses to living bone, the
trends of bone cement use have evolved.8 Also in the early 1970s, an infection rate of over 7% led to addition of antibiotics
to the bone cement.9 At that time, the aminoglycosides proved to be the best and most practical antibiotics, because of their
antibiotic spectrum and also because of their chemical properties. For example, gentamicin exhibits extreme stability during
sterilization procedures, manufacturing processes, and over its shelf life; furthermore, it is resistant to the temperatures
that occur during the polymerization process, and it is readily delivered from the polymers, moreover it acts locally in high
concentrations without any systemic adverse effects.
In the 1970s, cement was preferred, as clinicians were pleased with the application and results of this new technique;
in the 1980s, cementless fixation techniques were preferred. During the 1990s and into the present, hybrid systems are
5

preferred. For example, many of todays total hip arthroplasty procedures use a cemented femur and a press-fit acetabulum
prosthesis; total knee arthroplasties use a cemented tibia and a patella with a press-fit femur prosthesis.
On May 6, 2003, the Center for Devices and Radiological Health (CDRH) of the U.S. FDA cleared the first antibiotic bone
cement preparation.10 The FDA noted that the indication for use of this product was for the fixation of prostheses to living bone
for use in the second stage of a two-stage revision for total joint arthroplasty. This was an important hallmark in the evolution
of bone cement, as the pre-blended product ensures consistency and uniformity of the antibiotic/cement mixture. Antibiotic
bone cements are used to prevent or to treat infections by eluting the antibiotic locally into the targeted tissues. Local delivery
of antibiotic reduces the potential for systemic toxicity and other adverse side effects. Worldwide, Tobramycin is used most
often and it is the most studied bone cement antibiotic. However, Gentamicin use is more common in the United States.11 Both
of these antibiotics are acceptable because they are available in powder form, thermostable, safe, provide broad antimicrobial
coverage, and they have a low incidence of allergic reactions. Gentamicin and tobramycin are the only antibiotics available in
commercial antibiotic laden bone cement; however, other antibiotics including vancomycin and cephalothin have been studied.
The historical evolution of bone cement is summarized in Table 1.
Table 1 Historical Evolution of Bone Cement
Year
1870

Development
Themistokles Gluck
First surgeon to implant a total knee prosthesis made of ivory in Germany

1930s

The stems were fixed with cement mixed of plaster and colophony
Otto Rohm
Synthesized a group of thermoplastics, i.e., acrylic polymers

1950s 1960s

These polymers replaced hard rubber as the base materials for dentures
Sir John Charnley
Developed the modern cementing technique
Used cold-cured PMMA to attach an acrylic cup to the femoral head and to seat a metallic femoral prosthesis;
First to realize that PMMA could be used to fill the medullary canal and to blend with the
bone morphology

1970s

U.S. FDA
Approved bone cement for use in hip and knee prosthetic fixation
Cement was the preferred technique for total joint fixation

1980s

Cementless fixation techniques were preferred

1990s - Present

Hybrid systems are the preferred technique

2003

U.S. FDA
Cleared the first antibiotic bone cement preparation

PMMA BONE CEMENT: WHAT IS IT?

Overview
In order to use PMMA safely and effectively, it is important to review its components. Polymethylmethacrylate is an acrylic
polymer that is formed by mixing two sterile components: a liquid methylmethacrylate monomer and a powered methylmethacyrlate-styrene co-polymer.12 The polymer component, is a finely divided white powder, and primarily it consists of beadshaped particles with a diameter typically of 40 microns. These particles contain, in addition to homopolymer PMMA and/or
methyl methacrylate (MMA) copolymers, one of the three activators of the polymerization process: benzoyl peroxide (BPO)
(so-called initiator); zirconia (ZrO2), or barium sulphate (BaSO4) to provide radiodensity; and an antibiotic.13 The liquid, as
the second component, mainly contains the monomer MMA and it is the second activator of the polymerization process,
N,N-Dimethyl para-toluidine (DMPT) (i.e., the so called accelerator) DMPT, and hydroquinone act as a stabilizer to prevent
self-curing of the monomer in the liquid during storage (see Table 2). When the two components are mixed, the liquid monomer polymerizes around the prepolymerized powder particles to form hardened PMMA. In the process, heat is generated;
this is called an an exothermic reaction. The polymerization process begins when the liquid, acrylic monomer wets the
powder particles. As the powder dissolves, an initiator in the powder is released that activates some monomer molecules,
which then attach to other monomer molecules, which, in turn, activates them. A chain is formed as the process continues,
with the addition of more monomer material. The end result is a soft, pliable, doughy material, which then hardens into a
cement-like PMMA complex. As each monomer is added, energy is expended in the form of heat; this palpable heat signals
to the user that polymerization has occurred.
Table 2 Components of Bone Cement
Powder
Polymer

Liquid
Monomer

Polymethylmethacrylate/copolymer (PMMA)
Initiator

Methylmethacrylate (MMA)
Accelerator

Benzoyl peroxide (BPO)

N, N-Dimethyl para-toluidine (DMPT)

Radio-opacifier

diMethyl para-toluidine (DMpt)

Stabilizer

Barium sulphate (BaSO4)

Hydroquinone

Zirconia (ZrO2)
Antibiotics (e.g., gentamicin)
As previously noted, PMMA is a filler, not an adhesive, i.e., it does not bond substances together; rather it acts like a mortar
or grout to fill the void between the surface of the implant and the interstitial spaces in the surrounding cancellous bone
(see Figure 1). Bone cement functions as a supportive material, that forms a mechanical bond between the cement and the
bone and the cement and the prosthesis. In arthroplasty procedures, it forms a bond between the bone, the cement, and the
prosthesis. 14,15 When hardened, bone cement forms a buffer between the bone and the prosthesis that evenly distributes
weight and other stresses that impinge on the prosthesis and bone.

Figure 1 Bone Cement Penetration

Bone Cement

Cement Penetration

Types of Bone Cement

It is also important to note that there are several types of bone cement in regards to its viscosity. Viscosity affects the bone
cements handling characteristics, handling time, and its penetration into the cancellous bone and therefore, the quality and
longevity of the fixation achieved. Optimum viscosity helps cement penetrate the bone for good attachment, i.e., the cement must
be liquid enough to be delivered and then to penetrate the interstices of cancellous bone. Viscosity is defined as a measure of
the resistance of a fluid to deformation under shear forces and it is commonly described as the thickness of a fluid.16 Viscosity
also represents the resistance to flow and it is thought to be a measure of fluid friction. To some extent, solids may have viscous
properties. Solid bodies, such as a cement mantle, which have elasticity and viscosity in a specific range of deformation and rate
of deformation, are called viscoelastic. There are two requirements for bone cement viscosity during the working phase: first,
viscosity must be sufficiently low to facilitate the delivery of the cement dough from the syringe to the bone site; secondly, it must
penetrate into the interstices of the trabecular bone. On the other hand, the viscosity of the bone cement should be sufficiently
high to withstand the back bleeding pressure, thereby avoiding the risk of the inclusion of blood into the cement. Blood inclusion
could significantly reduce the stability of the bone cement. It is important that the cement retains an optimized viscosity for an
adequate duration to allow a comfortable working time. Low, medium and high viscosity cements are described below.

Low viscosity cements These cements remain in a runny state for a much longer period of time as compared to medium
or high viscosity cements. Typically they have a long waiting phase. The true working time in which the cement can be
picked up with a gloved hand usually is short, and the setting time can vary.
Medium viscosity cements These types of cements can offer versatility for various types of procedures. Medium viscosity
cements are both low and high in viscosity, depending on the time at which the cement is delivered. Medium viscosity
cements are considered to be dual phase cements. They begin in a low viscosity state while being mixed, which allows for
the easy and homogenous mixing of the powder and the liquid.
High viscosity cements These types of cements primarily are comprised of PMMA with no methylmethacrylate-styrenecopolymer content; they have no runny state at all. Immediately after mixing, the cement is doughy and ready to apply by
hand to the implant surface. The working time for high viscosity cements needs to be closely monitored; it is not always
easy to determine the end of the working time before it is too stiff to interdigitate with the bone.

The American Society for Testing and Materials (ASTM) F451 08 Standard Specification for Acrylic Bone Cement also
addresses the various types of bone cement.17 This standard covers self-curing resins which primarily are used for the
fixation of internal orthopedic prostheses. While a variety of copolymers and comonomers may be incorporated, the
composition of the set cement shall contain poly(methacrylic acid esters) as its main ingredient. The mixture may be used
in either the predough or dough stages. The ASTM specification also addresses compositional, physical performance,
and biocompatibility, as well as packaging requirements. Materials shall be tested and shall conform to specified values of
appearance, stability, sterility, viscosity, intrusion and compressive strength.

INDICATIONS FOR THE USE OF BONE CEMENT

PMMA bone cement is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of
polymer or metallic prosthetic implants to living bone.18
Other indications include:
Joint deterioration due to rheumatoid arthritis, osteoarthritis, or traumatic arthritis

Avascular necrosis

Sickle cell anemia

Collagen disease

Severe joint destruction secondary to trauma or other conditions

Revision of a previous arthroplasty

Fixation of pathological fractures where loss of bone substance or recalcitrance of the fracture renders more
conventional procedures ineffective

Factors that support the rationale for use includes aseptic loosening; unsuccessful results with uncemented femoral
components; continuing improvements in cementing techniques; and the escalating cost of press-fit, porous coated hip
and knee implants.

CONTRAINDICATIONS TO THE USE OF BONE CEMENT

PMMA bone cement is contraindicated in the presence of active or incompletely treated infection, at the site where the
bone cement is to be applied.19
The use of PMMA is also contraindication for patients who:
Are pregnant or nursing

Are allergic to the antibiotic or any of the other components of PMMA

Have a history of hypersensitivity or serious toxic reactions to aminoglycosides, e.g., gentamicin or vancomycin,
due to the known cross-sensitivity of patients to drugs in this class. For example, there may be increased risk of
ototoxicity from gentamicin, if drugs such as cisplatin and vancomycin are administered at the same time.
Have an active infectious arthritis of the joint or joints to be replaced or a history of such an infection
Have a loss of musculature or have neuromuscular compromise in the affected limb, this would render the procedure
unjustifiable

Have myasthenia gravis

Have metabolic disorders which may impair bone formation

9

Are hypotensive

Have renal impairment

Have congestive heart failure

SELECTION CRITERIA
The following are brief criteria for selection of both the patient as well as the appropriate type of bone cement for a specific
surgical procedure.

Patient Selection Criteria

Key patient selection criteria related to the use of bone cement include the following factors:

Activity level the patients activity level, i.e., is he or she relatively active or relatively sedentary? This will affect the
selection of the type of bone cement to be used.
Health status the overall health status of the patient must be considered, as the bone cement induces a drop in
blood pressure.
Osteoporosis bone density and disease must be assessed, as well as the presence of bone cysts and voids.

Bone Cement Selection Criteria

Selection of the optimal bone cement for a specific clinical application depends on several variables, including its chemical
composition and mechanical properties.

10

Chemical composition The primary determinant of the fatigue life of the various types of commercially available
bone cements is their basic chemical composition. Variables such as powder (bead) size, molecular weight, and the
addition of copolymers and radiopaque materials are important in determining the fatigue behavior of a particular type
of bone cement. Each brand of bone cement has a slightly different composition.
Mechanical properties Bone cement is evaluated for use based on the following five mechanical properties:
o
Fatigue strength this is a measure of the cements durability over time. It is an important factor, as patients are living longer and staying more active.
o

Compressive strength this measures the cements durability during weight bearing.

Flexural strength this is a measure of the cements ability to withstand bending stresses, such as
those experienced while walking, climbing stairs, or rising from a chair.

Impact strength this is a measure of the cements ability to withstand sudden impacts, such as those
which occur from a fall.

Creep creep measures the cements reaction to a combination of compressive and shear forces.
These forces occur during a variety of normal activities of daily living over time. Creep, also known as
plastic deformation, essentially is a mechanical problem that slowly and steadily can erode the long-term
performance of an implant. As noted, bone cement is an acrylic, and it is similar to other plastics, in
that it undergoes relaxation over time. All bone cements creep to some degree; however, cements with
higher porosity and viscosity are less resistant to creep deformation.

PMMA BONE CEMENT PREPARATION

In this section, the different components and formulations of bone cement, the phases of the polymerization process, the
various types of bone cement, and the criteria for selecting the appropriate cement type will be reviewed.
Processing and Handling of Bone Cement
It is important that the personnel involved in the preparation and mixing of PMMA bone cement understand the handling
characteristics and the setting times of the various types of cement. These factors directly impact surgery time and surgical
outcomes. Once the liquid and powder components are mixed during the routine application of acrylic bone cement in a
surgical procedure, the polymerization process is divided into four phases: mixing, waiting, working, and hardening. 20,21

Mixing Phase. The mixing phase starts with the addition of the liquid to the powder and ends when the dough is
homogenous and stirring becomes effortless. When the liquid and powder components of the cement are mixed
together, the liquid wets the surface of the prepolymerized powder. Because PMMA is a polymer that dissolves in
its monomer (which is not the case for all polymers), the prepolymerized beads swell and some of them dissolve
completely during mixing. This dissolution results in a substantial increase in the viscosity of the mixture; however, at
this stage the viscosity is still relatively low, compared with the later phases of polymerization. At the end of the mixing
phase, the mixture is a homogenous mass and the cement is sticky and has a consistency similar to toothpaste.
Waiting Phase. The mixing phase is followed by a waiting period to allow further swelling of the beads and to permit
polymerization to proceed. This leads to an increase in the viscosity of the mixture. During this phase, the cement turns
into sticky dough. This dough is subsequently tested with gloved fingers every 5 seconds, using a different part of the
glove on another part of the cement surface on each testing occasion. This process provides an indication of the end of
the waiting phase when the cement is neither sticky nor hairy.
Working Phase. The beginning of the working phase occurs when the cement is no longer sticky, but is of sufficiently
low viscosity to enable the surgeon to apply the cement. During this period, polymerization continues and the viscosity
continues to increase; in addition, the reaction exotherm associated with polymerization leads to the generation of
heat in the cement. In turn, this heat causes thermal expansion of the cement, while there is a competing volumetric
shrinkage of the cement as the monomer converts to the denser polymer. During the working phase, the viscosity of
the cement must be closely monitored because with a very low viscosity, the cement would not be able to withstand
bleeding pressure. This would result in blood lamination in the cement, which causes the cement to weaken. This phase
is completed when the cement does not join without folds during continuous kneading by hand; at this point, an implant
can no longer be inserted (Figure 2). Therefore, the prosthesis must be implanted before the end of the working phase.

Figure 2 Working Phase: Testing the Cement22

Hardening or Setting phase. The last phase is the hardening or the setting period, in which the polymerization stops and
the cement cures to a hard consistency. As noted, the prostheses must be in place prior to this phase. The temperature
of the cement continues to be elevated, but then slowly decreases to body temperature. During this phase, the cement
continues to undergo both volumetric and thermal shrinkage as it cools to body temperature. The cement is ready for
11

implantation when two cement balls are touched to each other and they stick together; if they do not stick together,
the cement is in the curing stage and should not be used to implant the prosthesis. If implantation is completed with
the cement in the curing stage, it could result in the cement delaminating or separating from the bone and/or the
prosthesis.
It is difficult to predict the hardening time with accuracy, due to the various factors in the OR which can alter the setting
times of the cement. These factors include the ambient environment in the OR, the patients body temperature, and the
thickness of the cement.
In general, all bone cements define doughing, working, and setting time:23

Dough time: starts from beginning of mixing and ends at the point when the cement will not stick to unpowdered
surgical gloves. This occurs approximately 2-3 minutes after the beginning of mixing for most PMMA cements.
Working time: this is the time from the end of dough time until the cement is too stiff to manipulate, usually about 5-8
minutes.
Setting time: from the beginning of mixing until the time at which the exothermic reaction heats the cement to a
temperature that is exactly halfway between the ambient and maximum temperature (i.e., 50% of its maximum
value) and is the dough + working times; usually about 8-10 minutes.

Factors that Affect Bone Cement Preparation

When preparing PMMA bone cement, only the mixing phase is considered to be constant; the waiting, working, and
hardening phases are dependent on several factors, as noted below. 24,25

The ambient temperature. The higher the temperature, the shorter the phases; the colder the temperature, the
longer the phases. Bone cement package inserts will provide specific information on the duration of each period
relative to temperature.
The mixing process. Mixing cement too quickly or too aggressively can hasten the polymerization reaction; this
will generate an increased amount of energy, resulting in a reduced setting time. In addition, the kneading process
required for medium-viscosity cement preparation results in a somewhat faster setting time than when low-viscosity
cement is used. In general, the lower the heat of polymerization, the longer the setting time, and the greater the heat
of polymerization, the shorter the setting time.
The type of cement. The various types of cement have different setting times.
The powder to liquid ratio. Each type of bone cement is packaged with the exact amounts of powder and liquid
required to produce a consistent end product. If more liquid, or less powder, than required is used, setting time will
be prolonged; on the other hand, if less liquid, or more powder is used, setting time will be shortened. It is important
to follow the manufacturers guidelines for mixing cement in order to have a consistent end product.

Bone Cement Additives

In recent years, various substances and compounds have been added to PMMA bone cement in an effort to reduce the
adverse effects of high heat from polymerization (such as tissue damage and necrosis) and to strengthen the bone cement
once it has hardened. These additives include nanoparticles of magnesium oxide (MgO) and barium sulfate (BaSO4)26, as
well as multi-walled carbon nanotubes to slow down setting time. Also nanoparticles of gold (Au) and porous pure titanium
(pTi) are used to increase cement strength.27,28,29 Allergic reactions to bone cement additives are not uncommon.30

12

Antibiotic Bone Cement31,32

As previously noted, the first preblended bone cement containing an antibiotic (tobramycin) became available for sale in
the United States in 2003. Information gathered from preclinical and clinical studies, as well as interviews with orthopedic
surgeons and infectious disease specialists, led to the choice of tobramycin. While tobramycin is the antibiotic most
frequently chosen by surgeons for mixing into bone cement in the US, formulations also are available with gentamicin.
Several factors influence the choice of antibiotic to be added to the bone cement; the antibiotic must:

be able to withstand the exothermic temperature of polymerization;

be available as a powder;

have a low incidence of allergy; and

be able to elute from the cement over an appropriate time period.

Several studies have demonstrated the efficacy of the use of antibiotic bone cement. An early study conducted by Sterling,
et al prospectively investigated a consecutive series of ten patients undergoing a cemented primary total hip replacement
(THR) for osteoarthritis in order to establish the elution characteristics of antibiotic (tobramycin) bone cement.33 There was a
direct correlation between the amount of tobramycin bone cement which was implanted and the amount of tobramycin that
was absorbed systemically; in addition, excellent local delivery was achieved with minimal systemic concentrations. The
authors therefore concluded that tobramycin bone cement is an efficient and safe method for the delivery of antibiotics after
THR.
Subsequently, Block and Stubbs conducted a systematic review of the literature to evaluate studies on the use of antibiotic
bone cement for reducing the risk of deep wound infection.34 This review included 22 articles which provided estimates
of the prophylactic effectiveness of antibiotic cement. In reducing deep wound infection, the use of antibiotic cement
consistently was superior to plain cement, similar to the use of systematic antibiotics, and independent and additive in effect
when combined with other prophylactic measures. The collective results nearly unanimously favored the prophylactic use of
antibiotic cement in primary arthoplasty procedures.

Other Additives to Promote Healing

As we have discussed, antibiotics commonly used as additives for PMMA bone cement include vancomycin, gentamycin,
and meropenem, in addition to tobramycin. Also, successful non-antibiotic bactericides that have been used as bone cement additives include quaternary ammonium compounds such as benzalconium chloride and cetyl pyridinium chloride.35

PMMA BONE CEMENT: MIXING AND APPLICATION

Mixing Techniques

Ultimately, clinical goal for the appropriate preparation of bone cement is to utilize mixing and application techniques that
minimize porosity and contamination. In addition, concerns over the hazards associated with bone cement have created the
need to reduce exposure of the OR staff. In pursuit of this goal, significant evolution of modern cement mixing techniques
has occurred since the introduction of bone cement used in arthroplasty . Now these techniques are designed to produce a
better end product and also to reduce the levels of monomer exposure in the OR and to minimize contact with the cement.
Bone cement mixing technique classifications are briefly described below.36 As always, with any cement mixing system, it is
important to follow the manufacturers instructions for use.

Bag or hand mixing. Cement mixing techniques originally began as bag or hand mixing. In this method, the liquid was
injected into a powder bag and mixed by kneading it into low viscosity cement.
13

Open bowl mixing. The next mixing technique was open bowl mixing. The liquid and powder were poured together into
a plastic or stainless bowl and then mixed with a spatula. This produced a cement of unpredictable quality, with high
porosity, due to air-filled spaces between the particles; air trapped between lumps of mixing material just before the
mixture becomes liquid; and the air introduced by the stirring during hand spatulation. This method also exposed the
OR staff to noxious fumes. The harmful effects of these fumes will be discussed in greater detail later.
Closed bowl mixing (see Figure 3). Subsequently, the closed bowl technique was developed to reduce personnel
exposure to the harmful, noxious PMMA fumes. This technique was the early paddle mixing system, which evacuated
the fumes by connection to the standard wall suction.

Figure 3 Closed Bowl Mixer

Centrifugation after mixing. Immediate centrifugation of the cement mixture after the mixing process reduces the size of
any entrapped air bubbles and, therefore, the porosity of the bone cement by spinning the powder and liquid together. This
reduction in porosity has been shown to increase the compressive strength and handling properties of centrifuged cement
substantially when compared to manually mixed specimens. The steps for the centrifugation of bone cement are as follows:
1. Chill the liquid monomer to negate the shortening effect of centrifugation on setting time.
2. Mix the powder and the chilled liquid together.
3. Introduce the resulting low-viscosity cement mixture into a cement syringe.
4. Place the syringe in the centrifuge.
5. Spin at high speed for a short period of time.

Vacuum mixing (see Figure 4). Vacuum mixing was the next development for mixing bone cement. Today, most
operating rooms mix bone cement under a partial vacuum, where the cement is mixed under ideal conditions. This
results in a smaller amount of air becoming entrapped in the cement during mixing. Vacuum mixing systems may
mix the cement in a cement syringe, in a bowl, or in a cement cartridge; the system remains closed up until cement
delivery. All of these systems consist of an enclosed chamber connected to a vacuum source, such as wall suction or
a dedicated vacuum pump; the vacuum source creates a partial vacuum during mixing. All ingredients are added and
mixed while the system is closed.

Figure 4 Vacuum Cement Mixer

14

With any type of vacuum mixing system, the components are added and mixed while the
following the same general procedure:
1. Wet the powder with the monomer.

system is closed,

2. Apply the vacuum while the mixing continues according to the manufacturers written instructions.
The entrapped air bubbles will be drawn off via the partial vacuum, thus reducing the porosity and
thereby increasing the fatigue strength of the cement.
3. The cement is then hand-packed or transferred to a cartridge with a spatula and a funnel.

High vacuum mixing. The next development in the cement mixing process is high vacuum mixing. A pump is used to
create an ideal vacuum of 20 - 22 millimeters of mercury. Paddle mixing is perfected in order to evacuate more air
from the cement by utilizing an ideal surface area and ensuring inclusion of all powder and liquid. The combination
of a closed vacuum system and carbon of a filter evacuates the harmful fumes. Also, this type of system allows for
automatic transfer of cement into the cartridge while under vacuum.
Cartridge mixing and delivery (see Figure 5). The latest advancement in bone cement mixing technique is a simple,
universal power mixer that quickly mixes and then mechanically injects all types of bone cement. This type of device
reduces mix times, as it requires fewer steps to load, mix, and transfer the cement. The rotary hand piece reduces
variability, which results in consistent mix times; a built-in charcoal filter reduces harmful fumes.

Figure 5 Cartridge Cement Mixing and Delivery

Application Techniques
The evolution of bone cement application techniques has paralleled that of mixing techniques. The methods for application
of bone cement include: hand packing, injection, and gun pressurization; these are outlined below briefly.37, 38 As with
cement mixing devices, the manufacturers instructions for any cement delivery system should be followed.

Hand packing. The original method of cement application was hand packing, where the femoral canal was packed
either by the hand or finger. The proximal end was packed with cement by pressing with the fingers or thumbs; this
pressurization forced the cement into the bone interstices. Commonly, in total knee arthroplasty, cementing is hand
packed since the surfaces are readily visualized, which facilitates hand packing.
Syringe injection. After hand packing, syringes are used to apply, or to inject, the cement. Syringes are the
predecessors to todays gun pressurization devices.
Injection with hand pressurization. With hand pressurization, the proximal end is pressurized by pressing with the
fingers or thumbs; this pressurization forces the cement into the bone interstices.
15

Injection with gun pressurization. The latest development in bone cement application methods is the gun
pressurization device. Injection with gun pressurization offers a mechanical advantage that allows the surgeon to
force more cement into the interstices at a greater rate of pressurization. Various pressurization tips allow more
cement to be forced tightly into the bone, while preventing overflow.

Factors that Weaken Bone Cement39, 40

Strict adherence to good cement application techniques is a key factor in reducing the rate of loosening and also in
increasing the long-term survival of joint arthroplasty. But, there are factors that weaken bone cement that must be
considered when mixing and applying bone cement. First, intrusion of foreign materials can weaken the cement. Often the
word contamination is used to describe the presence of unwanted matter in bone cement; however, in the perioperative
setting, typically the word contamination is associated with pathogenic invasion. Therefore, the word intrusion is better
used in describing the effects that water, saline, blood, bone chips, or fat have on the setting time and the integrity of the
hardened cement. Either a prolonged or a reduced setting time depends on the type and the volume of unwanted material
that is introduced. Also, the presence of intrusion may cause laminations, which are faults or folds in the bone cement.
Laminations create potential areas of weakness in the cement mantle where a failure can occur. Also, when the surgeon is
trying to achieve a good interlock between cement, bone, and prosthesis they can create difficulties.
The second factor that can affect the longevity of the attachment achieved by bone cement is the viscosity of the
polymerizing mix at the time it is introduced into the bone. The cements viscosity affects its handling characteristics, its
handling time, and its penetration of the cement into the cancellous bone. Optimum viscosity helps the cement penetrate the
bone for good attachment of the prosthesis.

SAFETY CONSIDERATIONS FOR PATIENTS AND HEALTHCARE PROFESSIONALS

Because the components of PMMA bone cement are toxic and highly flammable, all members of the perioperative team
must be aware of the potential hazards associated with the use of PMMA for both personnel and patients in the OR
environment. Appropriate safety precautions must be implemented to reduce the risk of exposure. Moreover, prior to using
any type of PMMA bone cement, personnel should receive training about its properties, handling characteristics, mixing, and
the application of bone cement.41 The specific hazards associated with bone cement and safety precautions are described
below.

Potential Exposure Hazards

16

Flammability.42, 43 Like many other materials used in the OR, methyl methacrylate is combustible, and it requires
special measures to ensure safe handling. As packaged, bone cement does not pose a fire hazard; but, the liquid
monomer is highly volatile and flammable with an open cup flash point of 50 degrees Fahrenheit. It is important never
to bring a spark or other ignition source (e.g. electrosurgery devices) near the surface of the liquid; therefore, proper
storage of electrosurgical devices MUST be practiced to avoid potentially dangerous situations. While the product is
considered stable, hazardous polymerization may occur and therefore, proximity to heat and ignition sources should
be avoided; also it may polymerize on exposure to light. It is incompatible with oxidizing agents, peroxides, bases,
acids, reducing agents, amines, halogens, and heat. Also, proper ventilation is an important factor in minimizing
the danger of fire or explosion in confined spaces. In order to eliminate the maximum amount of monomer vapor,
the OR should be adequately ventilated. The typical OR ventilation system is considered adequate for preventing
a potentially hazardous build-up of monomer vapors. However, toxic gases and vapors, such as carbon monoxide,
may be released in fires involving methylmethacrylate. In the unlikely event of a fire, the usual fire-fighting procedures
are required. The fire can be extinguished with dry chemical, alcohol, polymer foam, or carbon dioxide extinguishers;
water spray should be used to cool fire-exposed containers. Those fighting the fire should wear self-contained
breathing apparatus and protective clothing to prevent contact with skin and eyes.
Health Hazards. Potential health hazards are posed for OR personnel and patients when bone cement is used. These
are described in detail below.

o Occupational hazards for OR staff. The adverse effects of liquid bone cement are the primary safety
concerns when preparing and working with bone cement. Members of the surgical team are exposed to the
monomer by skin contact and inhalation of vapors.44 The degree of potential hazard to the surgical team
from the inhalation of the monomer vapor depends on its concentration level in the OR. The permissible
exposure limit (PEL) value established by OSHA is a time-weighted average limit of 100 parts per million
(ppm) of air or a time-weighted average of 410 milligrams per cubic meter of air during any 8-hour work
shift in a 40-hour work week.45
-- Generally, methyl methacrylate is classified as an irritant. Excessive exposure to vapors can
produce eye or respiratory tract irritation.46, 47 Exposure to high concentrations of the vapor
may cause headache, dizziness, dyspnea, generalized erythroderma, and at very high levels,
drowsiness and even loss of consciousness. Exposure to the liquid can cause considerable
irritation or burns to the eyes; skin contact with the liquid monomer may produce irritation or burns.
Allergic skin sensitization can also occur over time. Corneal ulcer has been reported to develop
from exposure to the vapors. It may be metabolized in the liver to form a mutagenic substance.
-- There are additional concerns regarding methyl methacrylate exposure for staff members who
wear soft contact lenses. The manufacturers of soft contact lenses have recommended that these
types of lenses be removed in the presence of noxious and irritating vapors. Soft contact lenses
are very permeable and should not be worn in an OR where methyl methacrylate is being mixed,
because the lenses are subject to pitting and penetration by the vapors.
o Health hazards for patients. PMMA bone cement presents potential health hazards for patients as well. The
adverse patient reactions to PMMA include transitory hypotension, cardiac arrest, cerebrovascular accident,
pulmonary embolus, thrombophlebitis, and hypersensitivity reactions; while uncommon, cardiac arrest and
death have occurred after application of bone cement.48 These adverse reactions have been attributed to
several factors, including a rise in the intramedullary canal pressure, which causes embolic events; a possible chemical and blood reaction, causing sudden hypotension; and certain preexisting patient conditions.
-- Bone cement implantation syndrome (BCIS) is a well-recognized complex of sudden physiologic
changes that occur within minutes of the implantation of methyl methacrylate bone cement to
secure a prosthetic component into the femur.49 For patients undergoing total hip arthroplasty with
cemented implants, cardiopulmonary changes have contributed to intraoperative mortality ranging
from 0.02% to 6.6% of the cases. Cardiac arrest and death are the most catastrophic symptoms
associated with cemented arthroplasty.

The underlying cause of the systemic hypotension and sudden cardiac failure is reported to
be right ventricular failure secondary to increased pulmonary artery pressure (PAP). Serious
embolization increases the PAP and pulmonary vascular resistance (PVR), causing the
right ventricle to dilate; these changes reduce left ventricular filling and cardiac output. The
resulting hypotension decreases coronary perfusion pressure. As right ventricular enddiastolic pressure increases, right coronary blood flow decreases, leading to low systemic
blood pressure and creating ischemia of the right ventricle. This process produces a vicious
cycle of right ventricular depression, failure, and death; as noted, these changes can occur
within minutes of inserting a cemented prosthesis. Embolization is enhanced when tissue
thromboplastin from the bone marrow is forced into the veins of the proximal femur during
prosthetic insertion; this activates a clotting cascade, lesions of the venous endothelium, and
thrombogenesis. Other theories about the cause of BCIS include:
The direct effect of the exothermic reaction of cement temperature
Air or gas embolism caused by polymerization of methyl methacrylate monomer
Hypersensitivity/anaphylactic reaction to the acrylic monomer
17

 Reflex bradycardia
Increase in intramedullary pressure resulting from the introduction of hot acrylic
cement (this increase could force marrow and fat into the circulation, producing
pulmonary emboli.)
Fat and debris from the femoral shaft embolize from the femoral canal during cement
and implant insertion.

Factors that increase a patients risk for BCIS include:

Elderly patients with underlying:

o cardiovascular disease and who are undergoing cemented arthroplasty for repair of a fracture
o severe osteoporosis
o malignancies especially involving the femur
o pulmonary disease

Patients with intertrochanteric or pathologic fractures

Patients who have pacemakers; who take sympathetic blockade medication; are hypotensive
or have inadequate volume replacement; have a patent foramen ovale; are hemodynamically
unstable at the time of cementing and prosthesis insertion; and have large femoral canals (e.g.,
21 mm or larger) requiring insertion of a long-stem femoral component.

Signs and symptoms of bone cement implantation syndrome may include one or more symptoms,
including but not limited to:

18

hypotension
pulmonary hypertension
increased central venous pressure
pulmonary edema
bronchoconstriction
anoxia or hypoxemia
decreased partial end tidal carbon dioxide
cardiac dysrhythmia or arrhythmia
cardiogenic shock
transient decrease in arterial oxygen tension
hypothermia
thrombocytopenia
cardiac arrest
sudden death

If the patient survives an initial episode, the syndrome is a time-limited phenomenon. The recovery time
ranges from a few seconds to approximately 24 hours.50 The patients chance of survival is increased if
the situation is immediately recognized and supportive measures are rapidly initiated (these measures
will be described below). To facilitate the early recognition of bone cement implantation syndrome, the
circulating nurse and the anesthesia provider should be familiar with the causes, risk factors, symptoms,
and preventative interventions (as described below).51

PRECAUTIONS TO MINIMIZE EXCESSIVE EXPOSURE TO PMMA IN THE OR

Based on the potential hazards associated with the use of PMMA for patients and health care workers in the OR
environment, personnel must implement appropriate safety precautions, as described below.

Recommended Practices

The potential hazards associated with the exposure of methyl methacrylate to any portion of the body in the perioperative
practice setting should be identified and safe practices should be established to reduce the risk of injury to staff members
and patients. Specific recommendations for the safe use of methyl methacrylate bone cement in the OR include:52

Material safety data sheet (MSDS) information for methyl methacrylate must be readily accessible to employees
within the practice setting. This information includes identification of hazards, precautions or special handling, signs
and symptoms of toxic exposure, and first aid treatments for exposure.
Methyl methacrylate should be handled according to its MSDS.
Personnel should read and follow all instructions provided on the container label or found on the MSDS provided by
the manufacturer of the chemical.
Methyl methacrylate fumes should be extracted from the environment; the fumes should be exhausted to the outside
air or absorbed through activated charcoal.
Vacuum mixers with fume extraction should be used to reduce the fume levels to which users are exposed.
Eye protection should be worn to prevent contact with eyes. As noted above, methyl methacrylate fumes may produce
an adverse reaction with soft contact lenses, leading to irritation and potentially, corneal ulceration. There is no
documented evidence of problems associated with hard contact lenses.
The manufacturers recommendations should be followed for mixing and the required personal protective equipment
(PPE).
A second pair of gloves should be worn when handling methyl methacrylate and should be discarded after use.
The manufacturers instructions should be followed regarding the composition of the second pair of gloves. Methyl
methacrylate may be absorbed through the skin and may also penetrate many plastic and latex compounds, leading
to dermatitis. The liquid component of the cement should not come in contact with gloves.
Instead of hand mixing, a cement gun should be used to decrease handling of the product. The cement mixture
should not be touched until it is the consistency of dough.
Spills and disposal. The Environmental Protection Agency (EPA) classifies the liquid portion of bone cement as a
hazardous substance; therefore, proper procedures are required for handling spills and disposal:53, 54
o For methyl methacrylate spills:
The area of the spill should be ventilated until the odor has dissipated.
All sources of ignition should be removed.
Appropriate PPE should be worn during the clean-up.
The spill area should be isolated.
The liquid component should be covered with an activated charcoal absorbent.
The waste product should be disposed of in a hazardous waste container.
o Methyl methacrylate is considered hazardous waste and should be disposed of according to state, local,
and federal regulations.

19

Measures to Reduce the Risk of BCIS55, 56

During the preoperative and preanesthetic assessments, the patients risk factors for BCIS, particularly the patients
cardiopulmonary reserve, should be evaluated. This data should be used to select the prosthesis, the surgical procedure,
and the techniques most likely to avoid cardiopulmonary complications. If necessary and medically feasible, delay the
procedure until the patients medical and cardiovascular status can be maximized.
Measures to reduce the risk of BCIS that may be implemented by the surgeon or anesthesia provider include, but are not
limited to the following:

using invasive hemodynamic monitoring when pre-existing cardiopulmonary problems exist and during cementing
maintaining a high level of arterial oxygenation and increasing inspired oxygen concentration by administering 100%
oxygen during the procedure

decreasing the concentration of a volatile agent (when using general anesthesia) prior to insertion of the prosthesis

maintaining normovolemia intraoperatively, especially at the time of cementing and insertion of the prosthesis

placing a venting hole into the femur, especially if using a long-stem prosthesis

avoiding bilateral hip replacements with cemented prostheses if cardiopulmonary dysfunction is present

using a noncemented prosthesis, especially if the patients mean arterial pressure decreases 20% to 30% below
baseline during canal reaming or plugging
performing thorough, pulsatile, high-pressure, high-volume lavage and brushing followed by drying of the
intramedullary canal of the femoral shaft

using a cement restrictor combined with other methods to reduce intramedullary pressures

using a low viscosity cement

mixing the bone cement in a vacuum

working the cement before insertion to remove volatile vasodilator compounds

using a cement gun to apply the cement under sustained low pressure

using a retrograde cement gun technique for cement insertion

using a vacuum tube along the linea aspera to drain the proximal femur, which reduces high intramedullary pressure
during cement and prosthesis insertion
introducing the prosthesis stem slowly into the cemented femoral canal, thereby reducing pressurization

The surgeon or anesthesia provider implements most of these preventative measures; however, it is critical that the
circulating nurse and all of the scrub personnel know the appropriate interventions. Understanding the techniques that
may prevent bone cement implantation syndrome assists perioperative personnel in preparing for possible event-related
changes in the patients condition, should they need to assist with these interventions. The US FDA requires hospitals and
other user facilities to report deaths and serious injuries associated with the use of medical devices, including bone cements
and bone void fillers.57 The health care organizations procedures should be followed for mandatory reporting.

Additional Exposure Control Methods58

Additional exposure control methods include:

20

Engineering controls. A local exhaust hood should be used to remove exhaust fumes from the area in which methyl
methacrylate is being mixed. A tent hood may be used, unless mixing can be done in a separately ventilated area.
Portable hoods are available for use in the OR.
Work practices. Health care workers should be instructed to avoid touching contaminated hands or gloves to their

eyes or mouths.

Medical monitoring. Pre-exposure data should be recorded for the skin and respiratory systems of workers who
may be exposed to methyl methacrylate. Thereafter, periodic monitoring should emphasize the skin and respiratory
systems.

Emergency First Aid Procedures

Emergency first aid procedures for exposure to PMMA bone cement include:59

In the event of an emergency, institute first aid procedures and send for first aid or medical assistance.
Eye exposure if methyl methacrylate gets into the eyes, immediately wash the eyes with large amounts of water,
lifting both the upper and lower lids occasionally. Get medical attention as soon as possible. Contact lenses should
not be worn when working with this chemical.
Skin exposure if the skin is exposed to methyl methacrylate, immediately flush the contaminated skin with water.
If methyl methacrylate soaks through the clothing, remove the clothing immediately and flush the skin with water.
Medical attention should be sought if the skin is irritated.
Breathing if a person breathes in large amounts of methyl methacrylate, he/she should be moved to fresh air
immediately. If breathing has ceased, perform artificial respiration. Keep the affected person warm and at rest. Get
medical attention as soon as possible. Properly trained individuals may assist the affected person by administering
100% oxygen.
Swallowing when methyl methacrylate has been swallowed, get medical attention immediately. If medical attention
is not immediately available, induce vomiting in the affected person (if he/she is conscious) by having him/her touch
the back of the throat with his/her finger or by giving him/her syrup of ipecac as directed on the package. Do not
induce vomiting if the person is unconscious.
Rescue Move the affected person from the hazardous environment. If the exposed person has been overcome,
notify someone else and implement the established emergency rescue procedures. Personnel should understand the
facilitys rescue procedures and know the locations of rescue equipment before the need arises.

INFORMATION RESOURCES
Numerous resources that provide additional information about the safe use of PMMA bone cement are available; these
include:

Manufacturers Guidelines. The manufacturers guidelines should always be followed for the type of bone cement
being used, as well as for the type of mixing and application system being used.
OSHA Hazard Communication Standard.60 The OSHA Toxic and Hazardous Substances, Hazard Communication
Standard, or the right to know directive, states that employees must be informed of the hazards associated with all
chemicals that are used in the work setting.
Material Safety Data Sheet (see Figure 6). As previously discussed, the MSDS for methyl methacrylate, provided by
the manufacturer, must be readily accessible in the perioperative practice setting. The MSDS contains information on
identification of the hazards, precautions or any special handling needed, signs and symptoms of toxic exposure, and
first aid treatment for exposures. Staff members should read and follow all instructions provided on the MSDS.

21

Figure 6 MSDS Label

Association of periOperative Registered Nurses (AORN) Recommended Practices for a Safe Care Environment of
Care state that potential hazards associated with chemicals used in the practice setting should be identified and safe
practices should be established for their use.61 Methyl methacrylate is identified as a potentially hazardous chemical in
the perioperative practice setting.

SUMMARY
PMMA bone cement has been used in cemented arthroplasty procedures for over 50 years. Today, it remains an important
component in achieving optimal patient outcomes. The quality of bone cement is determined by several factors, including
the type of cement selected, the mixing and application processes, and its viscosity; therefore, its effectiveness is highly
dependent upon the use of appropriate mixing and application techniques. Additionally, the use of bone cement in the
perioperative environment is associated with certain hazards for both patients and personnel. In the OR, bone cement must
be handled and prepared properly in order to maximize its clinical benefits and also to protect patients and members of
the surgical team from its potential adverse effects. All members of the surgical team involved in the preparation and use
of bone cement must understand the clinical considerations related to its proper use thoroughly, as well as the appropriate
measures for safe handling and emergency procedures in cases of spills or exposure incidents. Education and training are
critical factors in the preparation and safe use of PMMA bone cement; through this knowledge and skill, both positive patient
outcomes and a safe perioperative environment of care can be achieved.

22

GLOSSARY
Accelerator
A catalytic agent used to hasten a chemical reaction.
Bone Cement Implantation Syndrome (BCIS) A grouping of symptoms that occurs within minutes after the
implantation of methyl methacrylate cement into the femoral canal.
Cancellous Bone
Bone that has a reticular, spongy, or lattice-like structure.
Colophony
A translucent, brittle substance derived from the stumps or sap of
various pine trees used in preparation of ointments and plasters.
Compressive Strength
The measure of bone cements durability during weight bearing.
Creep
The measure of bone cements reaction to a combination of
compressive and shear forces that occur during a variety of normal
activities of daily living over time.
Doughing Time
The limited period of time in which to apply, i.e., the cement should be
applied while the mixture is still doughy.
Erythroderma
Abnormal redness of the entire surface of the skin.
Exothermic Reaction
A chemical reaction (i.e., a process in which one or more substances
are changed into others) accompanied by the production of heat.
Fatigue Strength
The measure of bone cements durability over time.
Flexural Strength
The measure of bone cements ability to withstand bending stresses,
such as those experienced while walking, climbing stairs, or rising from
a chair.
Handling Time
The difference between the doughing time and the time that the cement
is set.
High Viscosity Bone Cement
Bone cement that is comprised primarily of PMMA with no methyl
methacrylate-styrene-copolymer content; with this type of cement, a
short waiting/sticky phase is followed by a long working phase. The
viscosity remains constant until the end of the working phase. The
hardening phase lasts between 1.5 and 2 minutes.
Impact Strength
The measure of bone cements ability to withstand sudden impacts,
such as those which occur from a fall.
Intrusion
The effect that water, saline, blood, bone chips, or fat have on setting
time and the integrity of the hardened cement.
Laminations
Faults or folds in bone cement.
Linea Aspera
A longitudinal ridge running down the posterior surface of the shaft of
the femur that extends proximally into three ridges to which various
muscles are attached.
Low Viscosity Bone Cement
Bone cement that has a long waiting phase of approximately 3 minutes;
the viscosity rapidly increases during the working phase and the
hardening phase is about 1 to 2 minutes long.
Medium Viscosity Bone Cement
Bone cement that has a long waiting phase of approximately 3 minutes,
but during the working phase, the viscosity only increases slowly;
hardening takes between 1.5 and 2.5 minutes.
Mutagenic Substance
An agent that induces a permanent change in the genetic material.
Parts Per Million (ppm)
Refers to a substance per million parts of air; it is a measure of the
substances concentration of volume in air.
Permissible Exposure Limit (PEL)
The permissible exposure limit of a hazardous substance, which is
enforceable by OSHA.
23

Polymerization

Polymethylmethacrylate (PMMA)
Porosity

Setting Time
Viscosity

Working Time

24

The bonding of two or more monomers (i.e., simpler molecules) to

form a polymer (i.e., a compound). The polymerization process is
an exothermic reaction, meaning it produces heat and is conversely
affected by the application of heat.
An acrylic cement-like substance used to secure prostheses to bone
during orthopedic surgery. Exposure usually occurs during mixing,
preparation, and in the operating room.
The presence of entrapped air in bone cement, formed as a result
of volatilization of the liquid component and mixing techniques.
Centrifugation and vacuum mixing methods, and pressurized cement
application can decrease the porosity of bone cement.
The time elapsed from the moment the powder and liquid components
are mixed until the cement is set.
The measure of the resistance of a fluid to deformation under shear
forces that is commonly described as thickness of a fluid; also
viscosity represents the resistance to flow and it is thought to be a
measure of fluid friction. The viscosity of bone cement affects its
handling characteristics, its handling time, and its penetration of the
cement into the cancellous bone.
The time required for bone cement to attain the correct consistency for
application to the bone once the ingredients of PMMA are mixed and
kneaded.

REFERENCES
1. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
2. Cluett J. What is bone cement? Available at: http://orthopedics.about.com/b/2008/05/18/what-is-bone-cement.htm.
Accessed August 4, 2011.
3. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
4. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
5. Breusch, SJ, and H Malchau. The Well-Cemented Total Hip Arthroplasty: Theory and Practice. Heidelberg, NY:
Springer-Berlin; 2005.
6. Fenton P, Rampurada A, Qureshi F. Bone cement, its history, its properties, and developments in it use. Available at:
http://usmorthopaedic.wordpress.com/2009/08/24/bone-cement-its-history-its-properties-and-developments-in-its-use/.
Accessed August 4, 2011.
7. Breusch, SJ, and H Malchau. The Well-Cemented Total Hip Arthroplasty: Theory and Practice. Heidelberg, NY:
Springer-Berlin; 2005.
8. Jiranek W. Antibiotic-loaded cement in total hip replacement: current indications, efficacy, and complications.
Orthopedics. 2005;28(8 Suppl): 873-77.
9. Buchholz HW, Elson RA, Engelbrecht E, Lodenkmper H, Rttger J, Siegel A. Management of deep infection of total hip
replacement. Journal of Bone and Joint Surgery. British Volume. 1981; 63-B(3): 342-353.
10. AAOS. June 2003 Bulletin. Available at: http://www2.aaos.org/aaos/archives/bulletin/jun03/innws.htm. Accessed
August 9, 2011.
11. Clyburn TA, Cui Q. Antibiotic laden cement: current state of the art. Available at: http://www.aaos.org/news/bulletin/
may07/clinical7.asp. Accessed August 9, 2011.
12. Bowen B. Orthopedic surgery. Alexanders Care of the Patient in Surgery, 14th ed.; JC Rothrock, Ed. St. Louis, MO:
Mosby; 2011: 741-742.
13. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
14. American Society for Testing and Materials. ASTM F451-08: Standard Specification for Acrylic Bone Cement. West
Conshohocken, PA: ASTM; 2008.
15. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
16. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
17. American Society for Testing and Materials. ASTM F451-08: Standard Specification for Acrylic Bone Cement. West
Conshohocken, PA: ASTM; 2008.
25

18. U.S. FDA. Class II special controls guidance document: Polymethylmethacrylate (PMMA) bone cement; guidance for
industry and FDA. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/
ucm072795.htm. Accessed August 5, 2011.
19. U.S. FDA. Class II special controls guidance document: Polymethylmethacrylate (PMMA) bone cement; guidance for
industry and FDA. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/
ucm072795.htm. Accessed August 5, 2011.
20. Bellare A. Orthopedic bone cement. The Adult Hip, Volume 1. Callaghan JJ, Rosenberg AG, Rubash HE, Eds.
Philadelphia, PA; Lippincott, Williams & Wilkins; 2007: 147. Also available at: http://books.google.com/books?id=CSaF
S5Tod3QC&pg=PA148&lpg=PA148&dq=bone+cement+doughing+time+working+time+handling+time&source=bl&ots=h
mk1svDA6a&sig=qF2yITjqLmaDJXqrEboa9K6zRKs&hl=en&ei=AUxBTo_CLOynsQKfrKG7CQ&sa=X&oi=book_result&c
t=result&resnum=6&ved=0CDUQ6AEwBQ#v=onepage&q&f=false. Accessed August 9, 2011.
21. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
22. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
23. Acrylic cement (PMMA). Available at: http://www.orthopaedia.com/display/Review/Acrylic+Cement+(PMMA). Accessed
August 4, 2011.
24. Ascherl R. Science of bone cement. Ortho Supersite. Available at: http://www.orthosupersite.com/view.asp?rID=3971.
Accessed August 4, 2011.
25. Dunne NJ, Xu Y, Makem J, Orr I. Ultrasonic characterization of the mechanical properties and polymerization reaction
of acrylic-based bone cements. Proceedings of the Institution of Mechanical Engineers. Part H. 2007; 221(3):251-261.
26. Ricker A, Liu-Snyder P, Webster TJ. The influence of nano MgO and BaSO4 particle size additives on properties of
PMMA bone cement. International Journal of Nanomedicine. 2008;3(1):125-32.
27. Ormsby R, McNally T, Mitchell C, Dunne N. Incorporation of multiwalled carbon nanotubes to acrylic based bone
cements: Effects on mechanical and thermal properties. Journal of the Mechanical Behavior of Biomedical Materials.
2010;3(2):136-145.
28. Shin HS, Sohn JI, Kim DC, et al. Density control of ZnO nanowires grown using Au-PMMA nanoparticles and their
growth behavior. Nanotechnology. 2009;20(8):85601.
29. Nakai M, Niinomi M, Akahori T, Tsutsumi H, Itsuno S, Haraguchi N, Itoh Y, Ogasawara T, Onishi T, Shindoh T,
Development of biomedical porous titanium filled with medical polymer by in-situ polymerization of monomer solution
infiltrated into pores. Journal of the Mechanical Behavior of Biomedical Materials. 2010;3(1):41-50.
30. Thomas P, Schuh A, Eben R, Thomsen M. Allergy to bone cement components. Der Orthopde. 2008; 37(2):117-120.
31. Jiranek W. Antibiotic-loaded cement in total hip replacement: current indications, efficacy, and complications.
Orthopedics. 2005;28(8 Suppl): 873-77.
32. Klekamp J, Dawson JM, Haas DW, DeBoer D, Christie M. The use of vancomycin and tobramycin in acrylic bone
cement: biomechanical effects and elution kinetics for use in joint arthroplasty. Journal of Arthroplasty. 1999;14(3):339346.
33. Sterling GJ, Crawford S, Potter JH, Koerbin G, Crawford R. The pharmacokinetics of Simplex-tobramycin bone cement.
Journal of Bone and Joint Surgery, British volume. 2003;85(5): 646-649.
26

34. Block JE, Stubbs HA. Reducing the risk of deep wound infection in primary joint arthroplasty with antibiotic bone
cement. Orthopaedics. 2005;28(11):1334-1345.
35. Mathey M, Surana V, Edwards M, Nicholson JW, A preliminary study of the release of quaternary ammonium
antimicrobial compounds from acrylic bone cement. Journals of Materials Science. Materials in Medicine. 2009;
20(7):1579-1583.
36. Eveleigh R. Principles of bone cement mixing. British Journal of Perioperative Nursing. 2001;11(1):18-20.
37. Eveleigh R. Principles of bone cement mixing. British Journal of Perioperative Nursing. 2001;11(1):18-20.
38. Madrala A, Nuo N. Effect of stem preheating and precooling on residual stress formation at stem/cement interface for
cemented hip implants. Journal of Biomedical Materials Research, Part B, Applied Biomaterials. 2010; 93(1):258-265.
39. American Society for Testing and Materials. ASTM F451-08: Standard Specification for Acrylic Bone Cement. West
Conshohocken, PA: ASTM; 2008.
40. Dunne NJ, Xu Y, Makem J, Orr I. Ultrasonic characterization of the mechanical properties and polymerization reaction
of acrylic-based bone cements. Proceedings of the Institution of Mechanical Engineers. Part H. 2007; 221(3):251-261.
41. Moss R, Bowers J. Orthopedic surgery. Competency for Safe Patient Care During Operative and Invasive Procedures.
Phippen ML, Ulmer BC, Wells MP, Eds Denver, CO; CCI; 2009: 959.
42. Material Safety Data Sheet. Methyl methacrylate. Available at: http://www.laddresearch.com/wsmsds/21335.pdf.
Accessed August 11, 2011.
43. Bowen B. Orthopedic surgery. Alexanders Care of the Patient in Surgery, 14th ed.; JC Rothrock, Ed. St. Louis, MO:
Mosby; 2011: 742.
44. CDC. NIOSH. Methyl methacrylate. Available at: http://www.cdc.gov/niosh/npg/npgd0426.html. Accessed August 11,
2011.
45. US Department of Labor, OSHA. Chemical sampling information: methyl methacrylate. Available at: http://www.osha.
gov/dts/chemicalsampling/data/CH_254400.html. Accessed August 9, 2011.
46. US Department of Labor. OSHA. Methyl methacrylate. Available at: http://www.osha.gov/dts/sltc/methods/organic/
org094/org094.html. Accessed August 11, 2011.
47. EPA. Methyl methacrylate. Available at: http://www.epa.gov/ttn/atw/hlthef/methylme.html. Accessed August 11, 2011.
48. Bowen B. Orthopedic surgery. Alexanders Care of the Patient in Surgery, 14th ed.; JC Rothrock, Ed. St. Louis, MO:
Mosby; 2011: 742.
49. Pennsylvania Patient Safety Advisory. Bone cement implantation syndrome. Available at: http://www.
patientsafetyauthority.org/ADVISORIES/AdvisoryLibrary/2006/Dec3(4)/Pages/01b.aspx. Accessed August 4, 2011.
50. Byrick RJ. Cement implantation syndrome: a time limited embolic phenomenon. Canadian Journal of Anaesthesia.
1997;44(2):107-111.
51. Burlingame B. Clinical issues: Bone cement implantation syndrome. AORN Journal. 2009; 89(2): 399-400.
52. AORN. Recommended practices for a safe environment of care. Perioperative Standards and Recommended
Practices. Denver, CO: AORN, Inc.; 2011: 215-236.
27

53. U.S. EPA. Methyl methacrylate. Available at: http://www.epa.gov/ttn/atw/hlthef/methylme.html. Accessed August 11,
2011.
54. Methyl methacrylate. Available at: http://www.cdc.gov/niosh/ipcsneng/neng0300.html. Accessed August 11, 2011.
55. Pennsylvania Patient Safety Advisory. Bone cement implantation syndrome. Available at: http://www.
patientsafetyauthority.org/ADVISORIES/AdvisoryLibrary/2006/Dec3(4)/Pages/01b.aspx. Accessed August 4, 2011.
56. Burlingame B. Clinical issues: Bone cement implantation syndrome. AORN Journal. 2009; 89(2): 399-400.
57. FDA. FDA Public Health Web Notification: Complications related to the use of bone cement and bone void fillers in
treating compression fractures of the spine. Updated May 7, 2004. Available at: http://www.fda.gov/MedicalDevices/
Safety/AlertsandNotices/PublicHealthNotifications/ucm062126.htm. Accessed August 11, 2011.
58. CDC/NIOSH. NIOSH Publication No. 88-119: Guidelines for protecting the safety and health of health care workers.
Available at: http://www.cdc.gov/niosh/docs/88-119/antineo.html. Accessed August 9, 2011.
59. NIOSH. Occupational health guideline for methyl methacrylate. Available at: http://www.cdc.gov/niosh/docs/81-123/
pdfs/0426.pdf. Accessed August 11, 2011.
60. Occupational Safety and Health Administration, Department of Labor. Toxic and hazardous substances, hazard
communication standard. Federal Regulations. Title 29 6: Parts 1910.1000; 29CFR1910.1200. Washington, DC: US
Government Printing Office; July 1, 1999:461- 469.
61. AORN. Recommended practices for a safe environment of care. Perioperative Standards and Recommended
Practices. Denver, CO: AORN, Inc.; 2011: 215-236.

28

Please close this window and

return to the main page to proceed
with taking the online test, evaluation
and registration.

29